Doctors safely added the vitamin D drug paricalcitol to chemotherapy in a small pancreatic cancer trial
Dana-Farber researchers safely combined paricalcitol, an approved vitamin D drug, with chemotherapy in a small trial in metastatic pancreatic cancer. Its strongest survival signal came in tumours rich in the vitamin D receptor, a possible way to choose patients that a larger trial still has to test.
Reality
- Evidence45
- Adoption
- Not scored
- Hype gap+40
- Incentives65
- Confidence50
Radiosurgery doubled median survival over whole-brain radiotherapy in a small cell lung cancer trial
NRG-CC009 found median survival of 17.4 months with radiosurgery versus 8.6 with whole-brain radiotherapy for small cell lung cancer brain metastases. Cognition, the primary endpoint, did not differ significantly, so radiosurgery's case here rests on survival.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+15
- Incentives
- Not scored
- Confidence50
Shih's lab standardizes the design of crisscross DNA megastructures in software
William Shih's group at the Wyss Institute and Dana-Farber has published a computational framework in Nature Communications for crisscross DNA megastructures, aimed at the unwanted-binding problem Shih says keeps the method in a few labs.
Reality
- Evidence58
- Adoption10
- Hype gap+30
- Incentives70
- Confidence45
Its authors say an 18-dimensional property grid, which decides which chemical subspaces get docked at all, cuts compute by orders of magnitude, and they back the platform with nanomolar inhibitors of two targets plus co-crystal structures.
Reality
- Evidence64
- Adoption20
- Hype gap+20
- Incentives66
- Confidence58
A pancreatic pill proves pan-RAS is druggable. Lung and colon will price the claim
Rasonque roughly doubled median survival against a 6.7-month chemotherapy arm in a cancer where nearly every tumor carries a KRAS mutation. Neither condition repeats in the bigger indications.
Reality
- Evidence60
- Adoption52
- Hype gap+27
- Incentives74
- Confidence50
Harvard's KinoPlex cuts 1.8 million phosphorylation sites down to 250,000 plausible ones
The atlas turns kinase-inhibitor selection into a matching problem. What is missing is evidence that the match predicts which drug works in a patient.
Reality
- Evidence55
- Adoption22
- Hype gap+18
- Incentives68
- Confidence45